Obstructive Sleep Apnea (OSA) is a widespread disease, but usually is an underdiagnosed and undertreated public health problem. Nowadays its study is expensive. Collaboration and involvement of all specialties are necessary, also the implementation of simplified diagnostic methods to try to improve detection, increase the diagnosis and treatment ratio.
View Article and Find Full Text PDFSolution-processed gain media have great technological potential as lasers due to their ease of integration with on-chip photonics, scalability and tuneable optoelectronic properties. Currently, the spectral coverage of solution-processed lasers extends from visible up to telecom wavelengths in the short-wave infrared (SWIR) (<1650 nm). Here, the optical gain in the extended SWIR from 1600 nm to 2500 nm is demonstrated, using PbSbased colloidal quantum dots (CQDs).
View Article and Find Full Text PDFIntroduction: Among all patients with hypertension, those with resistant hypertension (RH) have the highest rates of subclinical organ damage (SOD). The prevalence of obstructive sleep apnea (OSA) is high in RH patients, and it could contribute to SOD. We aimed to investigate how OSA and its treatment are related to SOD in a large cohort of RH patients.
View Article and Find Full Text PDFBackground: There is a close relationship between obstructive sleep apnoea (OSA) and resistant hypertension (RH). However, studies assessing the long-term effect of diagnosing and treating OSA on blood pressure (BP) control in these patients are lacking.
Methods: To address this gap, we recruited 478 RH patients from hypertension units and followed them prospectively after they were screened for OSA through a sleep study.